FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944741549> ?p ?o ?g. }

• W2944741549 endingPage "912" @default.
• W2944741549 startingPage "907" @default.
• W2944741549 abstract "Pre-eclampsia is multisystem metabolic diseases, commonly accompanied by hypertension and proteinuria, which are among the important causes of maternal and perinatal mortality and morbidity worldwide. In a pre-eclampsia animal model study in the last year, Elabela (ELA) infusion was reported to correct hypertension and proteinuria and to normalise the birth weights of the offspring. Therefore, our main goal in this human study is to compare ELA, apelin (APLN) and nitric oxide (NO) levels in the maternal blood of pregnant women with pre-eclampsia and severe pre-eclampsia and in their newborns’ venous-arterial cord blood with maternal blood of healthy pregnant women and their newborns’ venous-arterial cord blood. Thirty controls, 28 pre-eclampsia and 24 severe pre-eclampsia cases and their newborns participated in this study. Maternal blood and newborn venous-arterial cord blood samples were collected from these patients. ELA, APLN and NO levels in these samples were measured by ELISA method. When the maternal blood ELA, APLN and NO amounts were compared with control groups, there was a significant decrease in both pre-eclamptic and severe pre-eclamptic women and this was more prominent in the women with severe pre-eclampsia. When ELA, APLN and NO levels in the newborn venous-arterial cord blood of control group was compared with that of severe pre-eclamptic and pre-eclamptic women; it was parallel with maternal findings. ELA, APLN and NO levels appear to play a role in the pathophysiology of pre-eclampsia. It is predicted that if these molecules, which are reduced due to pre-eclampsia and severe pre-eclampsia, are brought to physiological limits in the future; pre-eclampsia related maternal and perinatal mortality and morbidity can be reduced.Impact StatementWhat is already known on this subject? There are two studies (one human and one animal) in the literature evaluating only maternal elabela (ELA) levels in pre-eclamptic pregnancies. The animal study demonstrated decreased blood ELA levels in pre-eclamptic animals and the human study found increased blood ELA levels in pre-eclamptic patients. There are no studies evaluating maternal ELA levels in severe pre-eclampsia patients and also there are no studies evaluating maternal ELA levels in pre-eclampsia and severe pre-eclampsia patients. There are no studies evaluating newborns’ venous-arterial blood APLN and NO levels. Apelin (APLN) and nitric oxide (NO) results were controversial in pre-eclampsia and severe pre-eclampsia patients.What the results of this study add? The present study, for the first time, demonstrates that decreased blood ELA, APLN and NO levels in maternal blood of pregnant women with pre-eclampsia and severe pre-eclampsia and in their newborns’ venous-arterial blood. Furthermore, we have also demonstrated for the first time that decreased ELA, APLN and NO are also related with low birth weights.What the implications are of these findings for clinical practice and/or further research? The low levels of ELA, APLN and NO in maternal blood and newborns’ venous-arterial blood may be the result or the cause of pathologic changes in pre-eclampsia and severe pre-eclampsia. Also, ELA, APLN and NO may be new indicator parameters of systemic endothelial dysfunction together. More studies are needed to evaluate the relationship between of ELA, APLN and NO and pre-eclampsia and severe pre-eclampsia and in newborns’ venous-arterial blood." @default.
• W2944741549 created "2019-05-16" @default.
• W2944741549 creator A5012385994 @default.
• W2944741549 creator A5025402982 @default.
• W2944741549 creator A5028192101 @default.
• W2944741549 creator A5033361470 @default.
• W2944741549 creator A5033675734 @default.
• W2944741549 creator A5074369258 @default.
• W2944741549 date "2019-05-07" @default.
• W2944741549 modified "2023-10-06" @default.
• W2944741549 title "Evaluation of elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns" @default.
• W2944741549 cites W1626926077 @default.
• W2944741549 cites W1976600554 @default.
• W2944741549 cites W1989706089 @default.
• W2944741549 cites W2036954961 @default.
• W2944741549 cites W2046194089 @default.
• W2944741549 cites W2056828374 @default.
• W2944741549 cites W2057454756 @default.
• W2944741549 cites W2067834484 @default.
• W2944741549 cites W2078660466 @default.
• W2944741549 cites W2079466440 @default.
• W2944741549 cites W2083350649 @default.
• W2944741549 cites W2084862932 @default.
• W2944741549 cites W2086742568 @default.
• W2944741549 cites W2087458930 @default.
• W2944741549 cites W2089162288 @default.
• W2944741549 cites W2116170728 @default.
• W2944741549 cites W2117074223 @default.
• W2944741549 cites W2160153755 @default.
• W2944741549 cites W2169557995 @default.
• W2944741549 cites W2260113709 @default.
• W2944741549 cites W2290475943 @default.
• W2944741549 cites W2583089302 @default.
• W2944741549 cites W2591695595 @default.
• W2944741549 cites W2728308062 @default.
• W2944741549 cites W2790193675 @default.
• W2944741549 cites W2797796956 @default.
• W2944741549 cites W2803865364 @default.
• W2944741549 cites W2804487705 @default.
• W2944741549 doi "https://doi.org/10.1080/01443615.2019.1572727" @default.
• W2944741549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31064239" @default.
• W2944741549 hasPublicationYear "2019" @default.
• W2944741549 type Work @default.
• W2944741549 sameAs 2944741549 @default.
• W2944741549 citedByCount "27" @default.
• W2944741549 countsByYear W29447415492019 @default.
• W2944741549 countsByYear W29447415492020 @default.
• W2944741549 countsByYear W29447415492021 @default.
• W2944741549 countsByYear W29447415492022 @default.
• W2944741549 countsByYear W29447415492023 @default.
• W2944741549 crossrefType "journal-article" @default.
• W2944741549 hasAuthorship W2944741549A5012385994 @default.
• W2944741549 hasAuthorship W2944741549A5025402982 @default.
• W2944741549 hasAuthorship W2944741549A5028192101 @default.
• W2944741549 hasAuthorship W2944741549A5033361470 @default.
• W2944741549 hasAuthorship W2944741549A5033675734 @default.
• W2944741549 hasAuthorship W2944741549A5074369258 @default.
• W2944741549 hasConcept C112672928 @default.
• W2944741549 hasConcept C126322002 @default.
• W2944741549 hasConcept C131872663 @default.
• W2944741549 hasConcept C170493617 @default.
• W2944741549 hasConcept C172680121 @default.
• W2944741549 hasConcept C203014093 @default.
• W2944741549 hasConcept C2776955114 @default.
• W2944741549 hasConcept C2779234561 @default.
• W2944741549 hasConcept C2779546753 @default.
• W2944741549 hasConcept C2779561371 @default.
• W2944741549 hasConcept C2780091579 @default.
• W2944741549 hasConcept C2780914630 @default.
• W2944741549 hasConcept C2781276381 @default.
• W2944741549 hasConcept C42407357 @default.
• W2944741549 hasConcept C43044207 @default.
• W2944741549 hasConcept C519581460 @default.
• W2944741549 hasConcept C54355233 @default.
• W2944741549 hasConcept C71924100 @default.
• W2944741549 hasConcept C84393581 @default.
• W2944741549 hasConcept C86803240 @default.
• W2944741549 hasConceptScore W2944741549C112672928 @default.
• W2944741549 hasConceptScore W2944741549C126322002 @default.
• W2944741549 hasConceptScore W2944741549C131872663 @default.
• W2944741549 hasConceptScore W2944741549C170493617 @default.
• W2944741549 hasConceptScore W2944741549C172680121 @default.
• W2944741549 hasConceptScore W2944741549C203014093 @default.
• W2944741549 hasConceptScore W2944741549C2776955114 @default.
• W2944741549 hasConceptScore W2944741549C2779234561 @default.
• W2944741549 hasConceptScore W2944741549C2779546753 @default.
• W2944741549 hasConceptScore W2944741549C2779561371 @default.
• W2944741549 hasConceptScore W2944741549C2780091579 @default.
• W2944741549 hasConceptScore W2944741549C2780914630 @default.
• W2944741549 hasConceptScore W2944741549C2781276381 @default.
• W2944741549 hasConceptScore W2944741549C42407357 @default.
• W2944741549 hasConceptScore W2944741549C43044207 @default.
• W2944741549 hasConceptScore W2944741549C519581460 @default.
• W2944741549 hasConceptScore W2944741549C54355233 @default.
• W2944741549 hasConceptScore W2944741549C71924100 @default.
• W2944741549 hasConceptScore W2944741549C84393581 @default.
• W2944741549 hasConceptScore W2944741549C86803240 @default.
• W2944741549 hasIssue "7" @default.

• next